GoodRx Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $200.4 million, exceeding expectations.

Adjusted EBITDA: $63.7 million, with an adjusted EBITDA margin of 31.8%.

Prescription Transactions Revenue: $106.4 million, consistent with prior guidance.

Pharma Direct Revenue: $61.6 million, up 76% year-over-year.

Subscription Revenue: $28.5 million, up 39% year-over-year.

Monthly Active Consumers: 5 million, down 12% year-over-year, attributed to seasonal factors and a shift towards subscription offerings.

2Strategic Updates and Business Highlights

Pharma Direct: Strong growth driven by consumer direct pricing programs and GLP-1 medication access. GoodRx has over 135 pricing programs, enhancing its role as a consumer access channel.

Subscriptions: The launch of GoodRx Companion in May is central to the strategy, offering affordable healthcare solutions. Subscriptions are now a primary focus, with a 14% increase in plans year-over-year.

Rx Marketplace: Performance aligned with expectations, with a deliberate shift towards subscriptions impacting prescription transaction revenue.

Employer Direct: Developing partnerships targeting GLP-1s and integrating GoodRx Companion to help employers manage prescription costs.

3Forward Guidance and Outlook

Revenue Guidance: Raised to $790 million - $805 million for the full year, indicating a return to year-over-year growth earlier than anticipated.

Adjusted EBITDA Guidance: Increased to $240 million - $250 million, reflecting confidence in profitable growth while investing in strategic priorities.

Pharma Direct Growth: Expected to exceed 70% year-over-year.

4Bad News, Challenges, or Points of Concern

Declining Monthly Active Consumers: The 12% year-over-year drop raises concerns about user engagement amidst the transition to subscription models.

MACs Decline: Continued decline in MACs (maximum allowable costs) could indicate challenges in traditional prescription revenue streams.

Market Pressures: Increased affordability pressures on consumers and changes in coverage (e.g., ACA and Medicaid) could impact business dynamics.

Leadership Transition: The recent change in CFO may introduce uncertainty during a critical growth phase.

5Notable Q&A Insights

Metrics Transition: Management acknowledged the need to evaluate and potentially update key performance indicators as the business model evolves, particularly in light of the shift from prescription transaction revenue to subscriptions.

Pharma Partnerships: The strong demand for GLP-1 medications is expected to continue, with GoodRx positioned as a key access channel.

Generics Market: The company remains focused on generics, which make up a significant portion of prescriptions filled, and will leverage this in its Companion strategy.

Navigating Relationships: The Employer Direct offering is seen as complementary to existing insurance plans, with no significant pushback from PBM partners anticipated. This summary encapsulates GoodRx's financial performance, strategic initiatives, forward guidance, and challenges, providing a comprehensive overview of the company's current standing and future outlook.